arrow
Back
M

Mehdi Touat

dana-farber cancer institute

35H-index
275Paper Count
6.8KCitation Count
Published Papers 108
Publication Date
A dependency map enhanced with next-generation 3D cancer models
errNature
IF48.5
err2026-08-05
err0
errOAAI
errJames V. Neiswender; Samuel Maffa; Lisa Brenan; Dina ElHarouni; Yejie Yun; Isabella Boyle; Kirsty Wienand; Haider Inam; Tate Bertea; Ashley Anderson; Megan Wong; Matias Enriquez; Evan Lenz; Beatriz Villafranca; Nora Shanks; Mary Hager; Nia Lloyd; Hannah Shadmany; Sarah J. Wie; Harry Liang; Konnor Yunghans; Xiaomeng Zhang; Lauren Golden; Hannah Harris; Serena Day; Philip Montgomery; Samantha Stokes; Ross M. Giglio; Cynthia Hajal; James R. Whittle; Guadalupe Garcia; Caitlin E. Mills; Mehdi Touat; Kristine Pelton; Hongyu Li; Prem Sai Prabhakar; Sonja Herter; Zoe Hoffmann Kamrat; Dan Gui; Julien Dilly; Chen Khuan Wong; Jimmy A. Guo; Sangita Pal; Yossef Baidi; Ryan Johnston; Daniel D. Brown; Sonam Bhatia; Peter S. Winter; Srivatsan Raghavan; Rameen Beroukhim; Eva Colas; David L. Spector; Adam J. Bass; Peter K. Sorger; Yu Chen; Sarah J. Hill; Steffi Oesterreich; Adrian V. Lee; Himisha Beltran; Jesse S. Boehm; Yuen-Yi Tseng; David E. Root; William C. Hahn; Andrew J. Aguirre; Catarina D. Campbell; Keith L. Ligon; Joshua M. Dempster; Tsukasa Shibue; Francisca Vazquez
errShare
errSave
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study
err2026-04-01
err0
PREAI
errCapucine Baldini; Philippe A. Cassier; Jean-Pierre Delord; Matteo Simonelli; Mehdi Touat; Lili Yao; J. Paul Duic; Alexander Gozman; Aurelien Marabelle
errShare
errSave
CTNI-09. VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
err2025-11-11
err0
errOAAI
errMarjolein Geurts; Emilie LeRhun; Giuseppe Minniti; Marta Padovan; Johnny Duerinck; Enrico Franceschi; Mehdi Touat; Andrea Pace; Felix Sahm; Julia Furtner; Nathalie Albert; Philipp Lohman; Martine van Zandvoort; Caroline Quoilin; Corinne Daumer; Eng-Siew Koh; Marshall Pitz; Thierry Gorlia; Michael Weller; Martin van den Bent; Matthias Preusser
errShare
errSave
Volumetric (3D) compared with traditional bidirectional (2D) assessment in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
err2025-11-01
err0
errOAAI
errEllingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
errShare
errSave
Preclinical and clinical assessment of chemoradiation after mutant IDH inhibitor treatment in IDH-mutant glioma
err2025-11-01
err0
errOAAI
errShi, Diana; Calvo-Fernandez, Ester; Puliyappadamba, Vinesh; Lanman, Tyler; Cruickshank, Aiden; Prost, Diego; Xiao, Yi; Neumann, Ethan; Gudipelly, Sriram; Clark, Louise; Kaphle, Pranita; Shipman, Tracey; Levitt, Michael; Lin, Mathew; Tsai, Alexander; Lee, Joyce; Simons, Donald; Tyagi, Ethika; Rahman, Rifaquat; De Nguyen, Quang-; Wen, Patrick; Haas-Kogan, Daphne; Yates, Kathleen; Manguso, Robert; Bardeesy, Nabeel; Bernstein, Bradley; Wu, Jingyi; Abdullah, Kalil; Jain, Payal; Tron, Adriana; Touat, Mehdi; Castro, L. Nicolas Gonzalez; Suva, Mario; Kaelin, William; Mcbrayer, Samuel
errShare
errSave
CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
err2025-11-01
err0
errOAAI
errPicca, Alberto; Belin, Lisa; Laurenge, Alice; Carpentier, Catherine; Chinot, Olivier; Moyal, Elizabeth Cohen-Jonathan; Djelad, Apolline; Bronnimann, Charlotte; Ducloie, Mathilde; Cuzzubbo, Stefania; Gourmelon, Carole; Taillandier, Luc; Younan, Nadia; Ramirez, Carole; Bauchet, Luc; Vauleon, Elodie; Langlois, Olivier; Bourg, Veronique; Dhermain, Frederic; Menei, Philippe; Seizeur, Romuald; Colin, Philippe; Ghiringhelli, Francois; Ricard, Damien; Deluche, Elise; Verlut, Clothilde; Faillot, Thierry; Khettab, Mohamed; Gaultier, Claude; Appay, Romain; Bielle, Franck; Idbaih, Ahmed; Tabouret, Emeline; Figarella-Branger, Dominique; Touat, Mehdi; Ducray, Francois; Dehais, Caroline
errShare
errSave
Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial
err2025-11-01
err0
errOAAI
errEllingson, Benjamin M.; Mellinghoff, Ingo; Van Den Bent, Martin J.; Blumenthal, Deborah T.; Touat, Mehdi; Peters, Katherine B.; Clarke, Jennifer L.; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P.; Ducray, Francois; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F.; Arakawa, Yoshiki; Sepulveda, Juan M.; Wick, Wolfgang; Soffietti, Riccardo; Perry, James; Giglio, Pierre; De La Fuente, Macarena, I; Maher, Elizabeth; Zhao, Dan; Pandya, Shuchi S.; Steelman, Lori; Hassan, Islam; Wen, Patrick Y.; Cloughesy, Timothy F.
errShare
errSave
EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)
err2025-11-01
err0
errOAAI
errReardon, David A.; Idbaih, Ahmed; Vieito, Maria; Ghiringhelli, Francois; Stradella, Agostina; Tabatabai, Ghazaleh; Burger, Michael C.; Mildenberger, Iris; Herrlinger, Ulrich; Wen, Patrick Y.; Touat, Mehdi; Wick, Antje; Gonzalez, Macarena; Hervieu, Alice; Gil-Martin, Marta; Renovanz, Mirjam; Gouttefangeas, Cecile; Maia, Ana; Chene, Laurent; Fagerberg, Jan; Rinaudo, Philippe; Wick, Wolfgang
errShare
errSave
A global, open-label, randomized Phase 3 trial evaluating niraparib compared to standard temozolomide therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
err2025-11-01
err0
errOAAI
errSanai, Nader; Mehta, Shwetal; Tien, An-Chi; Tovmasyan, Artak; Harmon, Jocelyn; Kennedy, William; Aziez, Amine; Chalmers, Anthony; Khasraw, Mustafa; Lim-Fat, Mary Jane; Minniti, Guiseppe; Sanchez, Juan-Manuel Sepulveda; Touat, Mehdi; Umemura, Yoshie
errShare
errSave
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial
err2025-10-29
err0
PREAI
errTimothy F Cloughesy; Martin J van den Bent; Mehdi Touat; Deborah T Blumenthal; Katherine B Peters; Benjamin M Ellingson; Jennifer L Clarke; Joe Mendez; Shlomit Yust-Katz; Liam Welsh; Warren P Mason; Francois Ducray; Yoshie Umemura; Burt Nabors; Matthias Holdhoff; Andreas F Hottinger; Yoshiki Arakawa; Juan M Sepulveda; Wolfgang Wick; Riccardo Soffietti; James Perry; Pierre Giglio; Macarena de la Fuente; Elizabeth Maher; Andrew Bottomley; Adriana E Tron; Denise Yi; Dan Zhao; Shuchi S Pandya; Lori Steelman; Islam Hassan; Patrick Y Wen; Ingo K Mellinghoff
errShare
errSave
Author Correction: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas
err2025-10-09
err0
errOAAI
errApril A. Apfelbaum; Eric Morin; Dominik Sturm; Georges Ayoub; Jeromy DiGiacomo; Sher Bahadur; Bhavyaa Chandarana; Phoebe C. Power; Margaret M. Cusick; Dana Novikov; Prem Prabhakar; Robert E. Jones; Jayne Vogelzang; Connor C. Bossi; Seth Malinowski; Lewis M. Woodward; Tania A. Jones; John Jeang; Sarah W. Lamson; Jared Collins; Kelly Y. Cai; Jacquelyn S. Jones; Sehee Oh; Hyesung Jeon; Jinhua Wang; Amy Cameron; Patrick Rechter; Angela De Leon; Karthikeyan Murugesan; Meagan Montesion; Lee A. Albacker; Shakti H. Ramkissoon; Cornelis M. van Tilburg; Emily C. Hardin; Philipp Sievers; Felix Sahm; Kee Kiat Yeo; Tom Rosenberg; Susan N. Chi; Karen D. Wright; Steven Hébert; Sydney Peck; Alberto Picca; Valérie Larouche; Samuele Renzi; Sara J. Buhrlage; Tejus A. Bale; Amy A. Smith; Mehdi Touat; Nada Jabado; Eric S. Fischer; Michael J. Eck; Lissa Baird; Olaf Witt; Claudia L. Kleinman; Quang-De Nguyen; Denise Sheer; Sanda Alexandrescu; David T. W. Jones; Keith L. Ligon; Pratiti Bandopadhayay
errShare
errSave
EARLY TUMOR VOLUME CHANGES PREDICT CLINICAL OUTCOMES IN MIDH1/2 GLIOMA: POST-HOC RESULTS FROM THE PHASE 3 INDIGO TRIAL
err2025-10-01
err0
errOAAI
errEllingson, B. M.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Welsh, L.; Mason, W. P.; Ducray, F.; Umemura, Y.; Nabors, B.; Holdhoff, M.; Hottinger, A. F.; Arakawa, Y.; Sepulveda, J. M.; Wick, W.; Soffietti, R.; Perry, J.; Giglio, P.; de la Fuente, M.; Maher, E.; Zhao, D.; Pandya, S. S.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.
errShare
errSave
DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES
err2025-10-01
err0
errOAAI
errAuffret, L.; Barry, C.; Ajlil, Y.; Tauziede-Espariat, A.; Simbozel, M.; Mayr, L.; Kergorhen, T.; Puiseux, C.; Riffaud, L.; Blouin, P.; Bertozzi, A.; Leblond, P.; Blomgren, K.; Froelich, S.; Picca, A.; Touat, M.; Sanson, M.; Beccaria, K.; Blauwblomme, T.; Dangouloff-Ros, V; Boddaert, N.; Gojo, J.; Filbin, M.; Varlet, P.; Debily, M.; Grill, J.; Castel, D.
errShare
errSave
PROGNOSIS IMPACT OF PROCARBAZINE AND/OR VINCRISTINE DISCONTINUATION IN FIRST-LINE TREATMENT BY PCV AND RADIOTHERAPY IN WHO GRADE 3 IDH-MUTANT DIFFUSE GLIOMAS
err2025-10-01
err0
errOAAI
errMeola, A.; Ndiaye, M. B.; Bertucci, A.; Carpentier, C.; Bequet, C.; Ahle, G.; Bihan, K.; Blazevic, I; Chinot, O.; Idbaih, A.; Hassani, L.; Larrieu, D.; Laurenge Leprince, A.; Cohen-jonathan Moyal, E.; Pouessel, D.; Touat, M.; Dehais, C.; Tabouret, E.
errShare
errSave
EXPLORATORY ANALYSES FROM PHASE 3 INDIGO STUDY SUGGEST POTENTIAL MECHANISM OF SEIZURE CONTROL THROUGH TUMOR VOLUME REDUCTION UNDER TREATMENT WITH VORASIDENIB
err2025-10-01
err0
errOAAI
errWick, W.; Mellinghoff, I. K.; van den Bent, M. J.; Blumenthal, D. T.; Touat, M.; Peters, K. B.; Clarke, J. L.; Mendez, J.; Welsh, L.; Mason, W. P.; Hottinger, A. F.; Sepulveda, J. M.; Soffietti, R.; Zhao, D.; Yi, D.; Weidl, D.; Steelman, L.; Hassan, I; Wen, P. Y.; Cloughesy, T. F.
errShare
errSave
Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment
err2025-10-01
err2
PREAI
errBellamy, Charlotte; Hajal, Cynthia; Ligon, Keith L.; Touat, Mehdi
errShare
errSave
CONDITIONAL SURVIVAL ANALYSIS IN IDH-MUTANT HIGH-GRADE GLIOMAS: AN USEFUL TOOL IN CLINICAL PRACTICE
err2025-10-01
err0
errOAAI
errPicca, A.; Belin, L.; Laurenge, A.; Carpentier, C.; Chinot, O.; Moyal, E.; Djelad, A.; Bronnimann, C.; Ducloie, M.; Cuzzubbo, S.; Gourmelon, C.; Taillandier, L.; Younan, N.; Ramirez, C.; Bauchet, L.; Vauleon, E.; Langlois, O.; Bourg, V; Dhermain, F.; Menei, P.; Seizeur, R.; Colin, P.; Ghiringhelli, F.; Ricard, D.; Deluche, E.; Verlut, C.; Faillot, T.; Khettab, M.; Gaultier, C.; Appay, R.; Bielle, F.; Idbaih, A.; Tabouret, E.; Figarella-Branger, D.; Touat, M.; Ducray, F.; Dehais, C.
errShare
errSave
VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
err2025-10-01
err0
errOAAI
errGeurts, M.; Le Rhun, E.; Minniti, G.; Padovan, M.; Duerinck, J.; Franceschi, E.; Touat, M.; Pace, A.; Sahm, F.; Furtner, J.; Albert, N.; Lohmann, P.; van Zandvoort, M. J.; Quoilin, C.; Daumer, C.; Koh, E.; Pitz, M.; Gorlia, T.; Weller, M.; van den Bent, M.; Preusser, M.
errShare
errSave
A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.
err2025-10-01
err0
errOAAI
errSanai, N.; Mehta, S.; Tien, A.; Tovmasyan, A.; Harmon, J.; Kennedy, W. R.; Aziez, A.; Chalmers, A.; Khasraw, M.; Lim Fat, M.; Minniti, G.; Sepulveda, J. M.; Touat, M.; Umemura, Y.
errShare
errSave
A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology
err2025-09-30
err0
errOAAI
errDrabent, Philippe; Touat, Mehdi; Benusiglio, Patrick R.; Euskirchen, Philipp; Coulet, Florence; Oumoussa, Badreddine Mohand; de la Fouchardiere, Arnaud; de Montpreville, Vincent Thomas; Jacob, Julian; Bernardeschi, Daniele; Laurent-Puig, Pierre; Sanson, Marc; Kalamarides, Michel; Bielle, Franck
errShare
errSave